A N 2 Alkyl substituted triazole derivatives and their synthesis method and application

By using DBU base in organic solvents to catalyze the reaction of triazole compounds with bromine/iodine, the problems of poor selectivity of N2-substituted triazole synthesis and harsh reaction conditions in the prior art are solved, and an efficient and gentle synthesis method is achieved , suitable for the wide application of pharmaceutical intermediates.

CN116178286BActive Publication Date: 2024-12-03EAST CHINA NORMAL UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202111422968.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-11-26
Publication Date
2024-12-03
Estimated Expiration
2041-11-26

AI Technical Summary

Technical Problem

The prior art has poor selectivity, harsh reaction conditions, complex steps and limited substrates when synthesizing N2-substituted triazoles and their derivatives, making it difficult to achieve an efficient and gentle synthesis method.

Method used

Using DBU base as an additive, react with triazole compounds and bromine/iodo in organic solvents, and efficiently synthesize highly selective N2 alkyl-substituted triazole derivatives through one-step reaction. The reaction conditions are mild, the time is short, and the steps are economical. , and has wide applicability.

Benefits of technology

The synthesis of N2 alkyl-substituted triazole derivatives with high selectivity (greater than 6:1) and high yield (greater than 80%) is achieved. It has the characteristics of simple operation, safe and efficient, and is suitable for intermediates in the pharmaceutical field. Production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention discloses a highly selective N 2 Alkyl substituted triazole derivatives and their synthesis methods and applications, using triazole compounds, bromides or iodides as raw materials, DBU base as an additive, in an organic solvent, through a one-step reaction, the product can be obtained with high selectivity and high yield. The method of the present invention has the advantages of good selectivity, mild reaction conditions, high yield, simple and safe operation and high efficiency. 2 The triazole skeleton contained in alkyl-substituted triazole derivatives is an important structural fragment of many complex natural products with biological activity. Therefore, this type of compound can be used as an important pharmaceutical and chemical intermediate and has broad application prospects in the pharmaceutical field.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of synthetic pharmaceutical chemicals, and specifically relates to a highly selective N 2 Alkyl-substituted triazole derivatives, synthesis methods and applications thereof. Background Art

[0002] N 2 Substituted triazole skeletons occupy an important position in natural products and active pharmaceutical ingredients [1] The existing synthesis methods are not perfect, have poor selectivity, and cannot efficiently synthesize N 2 Substituted triazoles and their derivatives. Development of a new method for the highly selective synthesis of N 2 Substituted triazole derivatives become an urgent scientific issue [2] .

[0003] Selectively substituted-1,2,3-triazoles have a wide range of biological activities, and several regioselective synthetic methods have been reported in the literature. However, the highly regioselective synthesis of 2,4-disubstituted 1,2,3-triazoles (N 2 Selectivity) remains challenging because the electron cloud density associated with the two terminal nitrogen atoms (N-1 and N-3) is higher than that of the vicinal N-2 nitrogen atom. [3] Some elegant strategies have been developed from NH-1,2,3-triazoles by exploiting the steric hindrance of the macromolecular group adjacent to the N-2 position, where the macromolecular group needs to be removed after synthesis. [4] Build N 2 Another strategy for the selective disubstituted 1,2,3-triazoles is to use N-sulfonyl-1,2,3-triazole as a starting point, which does not require the introduction of bulky groups to improve selectivity. 2 Selective product methods require high temperatures (>65°C) and long reaction times (>2 hours) [5] , and most methods are extremely limited in their substrate range. Summary of the invention

[0004] The present invention overcomes the defects of the above-mentioned prior art and provides a highly selective N 2 The method for synthesizing alkyl-substituted triazole derivatives has the advantages of high step economy, wide regional selectivity and substrate applicability, mild reaction conditions, high yield, simple and safe operation, and short reaction time (10-30 min). 2 Alkyl-substituted triazoles and their derivatives can be used as important pharmaceutical and chemical intermediates and have broad application prospects in the pharmaceutical field.

[0005] The present invention proposes a N 2 The alkyl-substituted triazole derivative has a structural formula as shown in formula (I):

[0006]

[0007] In formula (I),

[0008] R 1 It is alkyl, benzyl, halogen-substituted benzyl, alkyl-substituted benzyl, alkoxy-substituted benzyl, nitro-substituted benzyl, ester group, substituted ester group, thiophene heterocyclic group, quinoline heterocyclic group, morpholine ring group, androsterone group, quinolyl group; wherein the substituent is alkyl, 2-chloroethyl, 2-fluoroethyl, n-butyl chloride, cycloalkyl;

[0009] R 2 is alkyl, phenyl, halogen-substituted phenyl, alkoxy-substituted phenyl, alkyl-substituted phenyl, trifluoromethyl-substituted phenyl, thiophene heterocyclic group, benzothiophene heterocyclic group, benzofuran heterocyclic group, quinoline heterocyclic group;

[0010] Preferably,

[0011] R 1 is phenyl, C1-C12 alkyl, C1-C10 alkyl-substituted phenyl, C1-C10 alkoxy-substituted phenyl, trifluoromethyl-substituted benzyl, nitro-substituted benzyl, ester group, substituted ester group, quinolyl; wherein the substituent is methyl, ethyl, 2-chloroethyl, 2-fluoroethyl, n-butyl, n-butyl chloride, cyclopentanyl, n-dodecyl;

[0012] R 2 is C1-C12 alkyl, phenyl, halogen-substituted phenyl, C1-C10 alkoxy-substituted phenyl, C1-C10 alkyl-substituted phenyl, trifluoromethyl-substituted phenyl, thiophene heterocyclic group, benzothiophene heterocyclic group, benzofuran heterocyclic group, quinoline heterocyclic group;

[0013] More preferably,

[0014] R 1 is phenyl, 4-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, p-methoxy-substituted phenyl, p-trifluoromethyl-substituted phenyl, benzothienyl, benzofuranyl, quinolyl;

[0015] R 2 is methyl, ethyl, 2-chloroethyl, 2-fluoroethyl, n-butyl, n-butyl chloride, cyclopentane, n-dodecyl, thienyl, quinolyl, morpholinyl, and androsterone;

[0016] The present invention also proposes a highly selective N 2Alkyl substituted triazole derivatives and synthesis methods thereof, wherein a triazole compound represented by formula (1), a bromide or iodide represented by formula (2), and DBU base as additives are reacted in an organic solvent to obtain a highly selective N- 2 Alkyl substituted triazole derivative; the reaction process is shown in reaction formula (II)

[0017]

[0018] In formula (II),

[0019] R 1 It is alkyl, benzyl, halogen-substituted benzyl, alkyl-substituted benzyl, alkoxy-substituted benzyl, nitro-substituted benzyl, ester group, substituted ester group, thiophene heterocyclic group, quinoline heterocyclic group, morpholine ring group, androsterone group, quinolyl group; wherein the substituent is alkyl, 2-chloroethyl, 2-fluoroethyl, n-butyl chloride, cycloalkyl.

[0020] R 2 is alkyl, phenyl, halogen-substituted phenyl, alkoxy-substituted phenyl, alkyl-substituted phenyl, trifluoromethyl-substituted phenyl, thiophene heterocyclic group, benzothiophene heterocyclic group, benzofuran heterocyclic group, quinoline heterocyclic group;

[0021] Preferably,

[0022] R 1 is phenyl, C1-C12 alkyl, C1-C10 alkyl-substituted phenyl, C1-C10 alkoxy-substituted phenyl, trifluoromethyl-substituted benzyl, nitro-substituted benzyl, ester group, substituted ester group, quinolyl; wherein the substituent is methyl, ethyl, 2-chloroethyl, 2-fluoroethyl, n-butyl, n-butyl chloride, cyclopentanyl, n-dodecyl;

[0023] R 2 is C1-C12 alkyl, phenyl, halogen-substituted phenyl, C1-C10 alkoxy-substituted phenyl, C1-C10 alkyl-substituted phenyl, trifluoromethyl-substituted phenyl, thiophene heterocyclic group, benzothiophene heterocyclic group, benzofuran heterocyclic group, quinoline heterocyclic group, and androsterone group;

[0024] More preferably, R 1 is phenyl, 4-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, p-methoxy-substituted phenyl, p-trifluoromethyl-substituted phenyl, benzothienyl, benzofuranyl, quinolyl;

[0025] R 2 It is methyl, ethyl, 2-chloroethyl, 2-fluoroethyl, n-butyl, n-butyl chloride, cyclopentane, n-dodecyl, thienyl, quinolyl, morpholinyl, and androsterone.

[0026] In the synthesis reaction of the present invention,

[0027] The molar ratio of the triazole compound of formula (1) to the bromine / iodide of formula (2) is 1:1.2-1:1.5; preferably, it is 1:1.2.

[0028] Wherein, the dosage of the additive DBU is based on the dosage of the triazole compound, which is 100%-200mol% of the triazole compound; preferably, it is 200mol%.

[0029] Wherein, the organic solvent is selected from one or more of DCM, DCE, EA, toluene, and acetonitrile; preferably, CH3CN.

[0030] The amount of the organic solvent is based on the substrate (1) triazole compound, so that the concentration of the triazole compound in the organic solvent is in the range of 0.05M-0.15M; preferably, the concentration of the triazole compound in the organic solvent is in the range of 0.10M.

[0031] Wherein, the reaction temperature is room temperature; preferably, 25°C.

[0032] Wherein, the reaction time is 10-30 min; preferably, 30 min.

[0033] The method specifically comprises the following steps: firstly dissolving the triazole compound represented by formula (1) in the organic solvent, adding the brominated or iodinated compound represented by formula (2) at room temperature, and finally adding DBU as an additive to react to obtain the highly selective N 2 Alkyl substituted triazole derivatives.

[0034] The organic solvent in the organic solvent solution is one or more of DCM, DCE, EA, toluene, acetonitrile, etc.; preferably, it is acetonitrile.

[0035] The method further comprises the step of separating and purifying the compound obtained by the reaction; the separation and purification is performed by column chromatography using a solution with a volume ratio of ethyl acetate:petroleum ether=1:20-1:30.

[0036] The chemical mechanism involved in the synthesis method of the present invention is shown in the following formula (III):

[0037]

[0038] Among them, R 1 , R 2 The definition of is the same as that of formula (II).

[0039] The present invention also proposes the N 2Application of alkyl-substituted triazole derivatives in the preparation of drugs with anti-tumor cell activity.

[0040] The tumor cells are one or more of MG63 osteosarcoma cells, HCT116 osteosarcoma cells, SJSA-1 osteosarcoma cells, and 143B osteosarcoma cells.

[0041] The beneficial effect of the present invention is to provide a highly selective N 2 Alkyl-substituted triazole derivatives and their synthesis methods and applications, using triazole compounds, bromides or iodides as raw materials, DBU base as an additive, in an organic solvent, through a one-step reaction, the product can be obtained with high selectivity (greater than 6:1) and high yield (greater than 80%). The method of the present invention has the advantages of good selectivity, mild reaction conditions, high yield, simple and safe operation and high efficiency. The N 2 The triazole skeleton contained in the derivatives of alkyl-substituted triazoles is an important structural fragment of many complex natural products with biological activity. Therefore, this type of compound can be used as an important pharmaceutical and chemical intermediate and has broad application prospects in the pharmaceutical field. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 The product obtained in Example 1 of the present invention 1 Schematic diagram of H NMR.

[0043] Figure 2 The product obtained in Example 1 of the present invention 13 Schematic diagram of C NMR.

[0044] Figure 3 The product obtained in Example 2 of the present invention 1 Schematic diagram of H NMR.

[0045] Figure 4 The product obtained in Example 2 of the present invention 13 Schematic diagram of C NMR.

[0046] Figure 5 The product obtained in Example 3 of the present invention 1 Schematic diagram of H NMR.

[0047] Figure 6 The product obtained in Example 3 of the present invention 13 Schematic diagram of C NMR.

[0048] Figure 7 The product obtained in Example 4 of the present invention 1 Schematic diagram of H NMR.

[0049] Figure 8 The product obtained in Example 4 of the present invention13 Schematic diagram of C NMR.

[0050] Fig. 9 The product obtained in Example 5 of the present invention 1 Schematic diagram of H NMR.

[0051] Fig.10 The product obtained in Example 5 of the present invention 13 Schematic diagram of C NMR.

[0052] Fig.11 The product obtained in Example 6 of the present invention 1 Schematic diagram of H NMR.

[0053] Fig.12 The product obtained in Example 6 of the present invention 13 Schematic diagram of C NMR.

[0054] Fig.13 The product obtained in Example 7 of the present invention 1 Schematic diagram of H NMR.

[0055] Fig.14 The product obtained in Example 7 of the present invention 13 Schematic diagram of C NMR.

[0056] Fig.15 The product obtained in Example 8 of the present invention 1 Schematic diagram of H NMR.

[0057] Fig.16 The product obtained in Example 8 of the present invention 13 Schematic diagram of C NMR.

[0058] Fig.17 The product obtained in Example 9 of the present invention 1 Schematic diagram of H NMR

[0059] Fig.18 The product obtained in Example 9 of the present invention 13 Schematic diagram of C NMR.

[0060] Fig.19 The product obtained in Example 10 of the present invention 1 Schematic diagram of H NMR.

[0061] Fig. 20 The product obtained in Example 10 of the present invention 13 Schematic diagram of C NMR.

[0062] Fig.21 The product obtained in Example 11 of the present invention 1 Schematic diagram of H NMR.

[0063] Fig. 22 The product obtained in Example 11 of the present invention 13 Schematic diagram of C NMR.

[0064] Fig.23 The product obtained in Example 12 of the present invention 1 Schematic diagram of H NMR.

[0065] Fig.24 The product obtained in Example 12 of the present invention 13 Schematic diagram of C NMR.

[0066] Fig.25 The product obtained in Example 13 of the present invention 1 Schematic diagram of H NMR.

[0067] Fig.26 The product obtained in Example 13 of the present invention 13 Schematic diagram of C NMR.

[0068] Fig. 27 The product obtained in Example 14 of the present invention 1 Schematic diagram of H NMR.

[0069] Fig.28 The product obtained in Example 14 of the present invention 13 Schematic diagram of C NMR.

[0070] Fig.29 The product obtained in Example 15 of the present invention 1 Schematic diagram of H NMR.

[0071] Fig.30 The product obtained in Example 15 of the present invention 13 Schematic diagram of C NMR.

[0072] Fig.31 The product obtained in Example 16 of the present invention 1 Schematic diagram of H NMR.

[0073] Fig.32 The product obtained in Example 16 of the present invention 13 Schematic diagram of C NMR.

[0074] Fig.33 The product obtained in Example 17 of the present invention 1 Schematic diagram of H NMR.

[0075] Fig.34 The product obtained in Example 17 of the present invention 13 Schematic diagram of C NMR.

[0076] Fig.35The product obtained in Example 18 of the present invention 1 Schematic diagram of H NMR.

[0077] Fig.36 The product obtained in Example 18 of the present invention 13 Schematic diagram of C NMR.

[0078] Fig.37 The product obtained in Example 19 of the present invention 1 Schematic diagram of H NMR.

[0079] Fig.38 The product obtained in Example 19 of the present invention 13 Schematic diagram of C NMR.

[0080] Fig.39 The product obtained in Example 20 of the present invention 1 Schematic diagram of H NMR.

[0081] Fig.40 The product obtained in Example 20 of the present invention 13 Schematic diagram of C NMR.

[0082] Fig.41 The product obtained in Example 21 of the present invention 1 Schematic diagram of H NMR.

[0083] Fig.42 The product obtained in Example 21 of the present invention 13 Schematic diagram of C NMR.

[0084] Fig.43 The product obtained in Example 22 of the present invention 1 Schematic diagram of H NMR.

[0085] Fig.44 The product obtained in Example 22 of the present invention 13 Schematic diagram of C NMR.

[0086] Fig.45 The product obtained in Example 23 of the present invention 1 Schematic diagram of H NMR.

[0087] Fig.46 The product obtained in Example 23 of the present invention 13 Schematic diagram of C NMR.

[0088] Fig.47 The product obtained in Example 24 of the present invention 1 Schematic diagram of H NMR.

[0089] Fig.48 The product obtained in Example 24 of the present invention 13Schematic diagram of C NMR. DETAILED DESCRIPTION

[0090] The present invention is further described in detail in conjunction with the following specific embodiments and drawings, and the protection content of the present invention is not limited to the following embodiments. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are included in the present invention and are protected by the attached claims.

[0091] Example 1

[0092] 2-Benzyl-4-phenyl-2H-1,2,3-triazole (3a)

[0093]

[0094] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole (0.2 mmol, 44 mg, 1.0 eq) and 2 mL of acetonitrile were added. Benzyl bromide (0.24 mmol, 41 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as the eluent and the mixture was purified by column chromatography to obtain 3a as a white solid in 88% yield (41 mg). 1 H NMR (400MHz, Chloroform-d) δ7.87 (s, 1H), 7.79 (d, J = 7.4Hz, 2H), 7.42 (t, J = 7.5Hz, 2H), 7.36–7.31 (m, 6H), 5.63 (s, 2H). 13 C NMR (101MHz, Chloroform-d) δ148.07,135.35,131.45,130.39,128.86,128.79,128.44,128.30,127.98,125.96, 58.75.

[0095] Example 2

[0096] 2-Benzyl-4-(4-chlorophenyl)-2H-1,2,3-triazole (3b)

[0097]

[0098] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-(chlorophenyl)-1H-1,2,3-triazole (0.2 mmol, 51 mg, 1.0 eq) and 2 mL of acetonitrile were added. Benzyl bromide (0.24 mmol, 41 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30: 1) was used as the eluent and the mixture was purified by column chromatography to obtain 3b as a white solid in 80% yield (41 mg). 1 H NMR (400MHz, Chloroform-d) δ7.84 (s, 1H), 7.72 (d, J = 7.9Hz, 2H), 7.30– 7.36 (m, 7H), 5.62 (s, 2H). 13 C NMR (101MHz, Chloroform-d) δ147.04,135.18,134.23,131.38,129.08,128.92,128.84,128.40,128.04,127.21,58.84.

[0099] Example 3

[0100] 2-Benzyl-4-(4-(trifluoromethyl)phenyl)-2H-1,2,3-triazole (3c)

[0101]

[0102] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazole (0.2 mmol, 58 mg, 1.0 eq) and 2 mL of acetonitrile were added. Benzyl bromide (0.24 mmol, 41 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, the mixture was purified by column chromatography using petroleum ether / ethyl acetate (30:1) as eluent to obtain 3c as a white solid in 80% yield (48 mg). 1 H NMR (400MHz, Chloroform-d) δ7.90 (d, J=10.5Hz, 3H), 7.67 (d, J= 7.9Hz, 2H), 7.37–7.35 (m, 5H), 5.64 (s, 2H). 19 F NMR(376MHz,Chloroform-d)δ -62.62. 13C NMR(101MHz,Chloroform-d)δ146.71,135.02,133.84,131.83,130.27 (q,J=32.6Hz),128.86,128.47,128.07,126.11,125.85(q,J=3.8Hz),124.09(d,J=272.0Hz),58.96

[0103] Example 4

[0104] 2-Benzyl-4-(p-tolyl)-2H-1,2,3-triazole (3d)

[0105]

[0106] In a 4mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-(p-tolyl)-1H-1,2,3-triazole (0.2mmol, 47mg, 1.0eq) and 2mL acetonitrile were added. Benzyl bromide (0.24mmol, 41mg, 1.2eq) and DBU (0.2mmol, 34mg, 2.0eq) were then added to the mixture respectively. The vial was capped and stirred at room temperature (25°C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as eluent, and the mixture was purified by column chromatography to obtain 3d as a white solid in 80% yield (48mg). 1 H NMR(400MHz,Chloroform-d)δ7.44(d,J=8.1Hz,2H),7.23–7.17 (m,2H),7.07–6.98(m,3H),6.94–6.87(m,3H),6.71(t,J=7.7Hz,1H),6.40(d,J =8.0Hz,1H),5.15(d,J=15.1Hz,1H),4.98(d,J=15.1Hz,1H),4.41(s,1H),3.81( s,3H),3.68(s,3H),3.22(dt,J=15.5,7.5Hz,1H),2.93–2.84(m,1H),2.46(d,J= 13.9Hz,1H),2.33–2.21(m,1H),1.07(s,3H).

[0107] 13C NMR (100MHz, CDCl3) δ179.66,159.27,142.67,136.68,129.59,128.02,127.86,125.30,125.18,122.89,120.77,118 .98,117.57,114.18,109.22,108.79,77.34,77.03,76.71,73.24,56.05,55.31,43.79,32.51,29.29,25.24,19.29. HRMS(ESI)Calcd.for:C 29 H 29 N2O3(M+H) + 453.2175, found:453.2178.

[0108] Example 5

[0109] 2-Benzyl-4-(4-ethylphenyl)-2H-1,2,3-triazole (3e)

[0110]

[0111] In a 4 mL sealed vial equipped with a stirring bar, 4-(4-ethylphenyl)-1-(methylsulfonyl)-1H-1,2,3-triazole 1e (0.2 mmol, 50 mg, 1.0 eq) and 2 mL of acetonitrile were added. Benzyl bromide (0.24 mmol, 41 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30: 1) was used as the eluent and the mixture was purified by column chromatography to obtain 3e as a white solid in 82% yield (43 mg). 1 H NMR(400MHz,Chloroform-d)δ7.83(s,1H),7.68(d,J=7.6Hz,2H), 7.35–7.31(m,5H),7.23(d,J=7.7Hz,2H),5.62(s,2H),2.38(s,3H). 13 C NMR(101MHz,Chloroform-d)δ148.13,138.33,135.42,131.25,129.54,128.77,128.26,127.97,127.56,125.86,58.69,21.32.MS(ESI)m / z:264.6(M+H) +

[0112] Example 6

[0113] 2-Benzyl-4-(4-(tert-butyl)phenyl)-2H-1,2,3-triazole (3f)

[0114]

[0115] In a 4 mL sealed vial equipped with a stirring bar, 4-(4-(tert-butyl)phenyl)-1-(methylsulfonyl)-1H-1,2,3-triazole 1f (0.2 mmol, 56 mg, 1.0 eq) and 2 mL of acetonitrile were added. Benzyl bromide (0.24 mmol, 41 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as the eluent and the mixture was purified by column chromatography to obtain 3f as a white solid in 81% yield (47 mg). 1 H NMR (400MHz, Chloroform-d) δ7.85 (s, 1H), 7.73 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 7.34 (s, 5H), 5.63 (s, 2H), 1.35 (s, 9H). 13 C NMR(101MHz,Chloroform-d)δ151.61,148.07,135.47,131.34,128.77,128.25,127.92,127.57,125.80,125.71,58.68,34.71,31.30

[0116] Example 7

[0117] 2-Ethyl-4-phenyl-2H-1,2,3-triazole (3g)

[0118]

[0119] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2 mmol, 45 mg, 1.0 eq) and 2 mL of acetonitrile were added. Ethyl bromide (0.24 mmol, 25 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30: 1) was used as the eluent and the mixture was purified by column chromatography to obtain 3 g of a white solid in 90% yield (31 mg). 1H NMR(400MHz,Chloroform-d)δ7.82(s,1H),7.78(d,J=7.5Hz,2H),7.42(t,J =7.3Hz,2H),7.34(t,J=7.2Hz,1H),4.51(q,J=7.2Hz,2H),1.61(t,J=7.2Hz,3H). 13 C NMR(101MHz,Chloroform-d)δ147.54,130.70,130.58,128.87,128.31, 125.86,50.09,14.92

[0120] Example 8

[0121] 2-Butyl-4-phenyl-2H-1,2,3-triazole (3h)

[0122]

[0123] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2 mmol, 45 mg, 1.0 eq) and 2 mL of acetonitrile were added. Then bromobutane 2c (0.24 mmol, 33 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as the eluent and the mixture was purified by column chromatography to obtain a white solid 3h in 87% yield (35 mg). 1 H NMR(400MHz,Chloroform-d)δ7.82(s,1H),7.79(d,J=7.4Hz,2H),7.42(t,J =7.5Hz,2H),7.33(t,J=7.3Hz,1H),4.45(t,J=7.1Hz,2H),2.02–1.95(m,2H),1.43–1.33(m,2H),0.96(t,J=7.4Hz,3H). 13 C NMR(101MHz,Chloroform-d)δ 147.47,130.62,128.86,128.28,125.86,54.81,31.83,19.78,13.55.MS(ESI)m / z:202.4(M+H) + .

[0124] Example 9

[0125] 2-Pentyl-4-phenyl-2H-1,2,3-triazole (3i)

[0126]

[0127] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2 mmol, 45 mg, 1.0 eq) and 2 mL of acetonitrile were added. Then bromopentane 2d (0.24 mmol, 36 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30: 1) was used as the eluent and the mixture was purified by column chromatography to obtain 3i as a white solid in 86% yield (37 mg). 1 H NMR(400MHz,Chloroform-d)δ7.82(s,1H),7.79(d,J=7.6Hz,2H),7.42(t,J =7.4Hz,2H),7.33(t,J=7.2Hz,1H),4.44(t,J=7.1Hz,2H),2.05–1.96(m,2H),1.40–1.31(m,4H),0.90(t,J=6.5Hz,3H). 13 C NMR(101MHz,Chloroform-d)δ 147.47,130.62,128.86,128.28,125.87,55.09,29.54,28.69,22.18,13.93.MS(ESI)m / z:216.6(M+H) + .

[0128] Example 10

[0129] 2-Dodecyl-4-phenyl-2H-1,2,3-triazole (3j)

[0130]

[0131] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2 mmol, 45 mg, 1.0 eq) and 2 mL of acetonitrile were added. Bromopentane 2e (0.24 mmol, 60 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as the eluent and the mixture was purified by column chromatography to obtain 3j as a white solid in 86% yield (52 mg). 1H NMR(400MHz,Chloroform-d)δ7.82(s,1H),7.79(d,J=7.5Hz,2H),7.42(t,J =7.4Hz,2H),7.34(t,J=7.2Hz,1H),4.45(t,J=7.0Hz,2H),2.00(t,J=8.0Hz,2H),1.40–1.27(m,18H),0.88(t,J=6.2Hz,3H). 13 C NMR(101MHz, Chloroform-d)δ147.46,130.60,128.85,128.27,125.86,55.12,31.93,29.83,29.64, 29.55,29.45,29.36,29.07,26.54,22.71,14.13.HRMS(ESI)C20H32N3Calcd.for(M+H) + 314.2582,Found:314.2591.

[0132] Embodiment 11

[0133] 2-Cyclopentyl-4-phenyl-2H-1,2,3-triazole (3k)

[0134]

[0135] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2 mmol, 45 mg, 1.0 eq) and 2 mL of acetonitrile were added. Bromocyclopentane 2f (0.24 mmol, 36 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30: 1) was used as the eluent and the mixture was purified by column chromatography to obtain 3k as a white solid in 85% yield (36 mg). 1 H NMR (400MHz, Chloroform-d) δ7.81 (s, 1H), 7.78 (d, J = 7.6Hz, 2H), 7.42(t,J=7.4Hz,2H),7.33(t,J=7.3Hz,1H),5.09–4.98(m,1H),2.27–2.17(m,4H),1.95(s,2H),1.79–1.68(m,2H). 13C NMR(101MHz,Chloroform-d)δ147.12, 130.77,130.36,128.82,128.19,125.85,66.12,32.90,24.42.MS(ESI)m / z:214.1 (M+H) +

[0136] Example 12

[0137] 2-Allyl-4-phenyl-2H-1,2,3-triazole

[0138]

[0139] In a 4mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2mmol, 45mg, 1.0eq) and 2mL acetonitrile were added. Then 2g (0.24mmol, 53mg, 1.2eq) and DBU (0.2mmol, 34mg, 2.0eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25°C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as eluent, and the mixture was purified by column chromatography to obtain 3l as a white solid in 81% yield (30mg). 1 H NMR(400MHz,Chloroform-d)δ7.86(s,1H),7.79(d,J=7.5Hz,2H),7.43(t,J=7.4Hz,2H ),7.35(t,J=7.2Hz,1H),6.18–6.07(m,1H),5.36–5.27(m,2H),5.08(d,J=5.9Hz,2H). 13 C NMR (101MHz, Chloroform-d) δ147.9,131.6, 131.2,130.3,128.8,128.4,125.9,119.2,57.4.

[0140] Embodiment 13

[0141] 2-Propargyl-4-phenyl-2H-1,2,3-triazole 3m

[0142]

[0143] In a 4mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2mmol, 45mg, 1.0eq) and 2mL acetonitrile were added. Then bromopropargyl 2h (0.24mmol, 28mg, 1.2eq) and DBU (0.2mmol, 34mg, 2.0eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25°C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as eluent, and the mixture was purified by column chromatography to obtain white solid 3m in 80% yield (30mg). 1 H NMR (400MHz, Chloroform-d) δ7.89(s,1H),7.79(d,J=7.5Hz,2H),7.43(t,J=7.3Hz,2H),7.36(t,J=7.2Hz,1H),5.26(s,2H),2.54(s,1H). 13 C NMR (101MHz, Chloroform-d) δ148.6,131.8,130.1,128.9,128.6,126.1,75.7,74.8,44.5.

[0144] Embodiment 14

[0145] 2-(1-Fluoroethyl)-4-phenyl-2H-1,2,3-triazole 3n

[0146]

[0147] In a 4mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2mmol, 45mg, 1.0eq) and 2mL acetonitrile were added. Then bromofluoroethane 2i (0.24mmol, 30mg, 1.2eq) and DBU (0.2mmol, 34mg, 2.0eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25°C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as eluent, and the mixture was purified by column chromatography to obtain white solid 3n in 87% yield (33mg). 1 H NMR (400MHz, Chloroform-d) δ7.89 (s, 1H), 7.80 (d, J = 7.6Hz, 2H), 7.43(t,J=7.4Hz,2H), 7.36(t,J=7.2Hz,1H), 4.99(t,J=4.7Hz,1H), 4.88(t,J=4.7Hz,1H), 4.78(t,J=4.7Hz,1H), 4.71(t,J=4.7Hz,1H).19 F NMR(376MHz, Chloroform-d)δ-223.09. 13 C NMR(101MHz,Chloroform-d)δ148.3,131.5,130.2, 128.9,128.5,125.9,81.1(d,J=173.7Hz),54.9(d,J=21.9Hz).HRMS(ESI)m / z:[M+Na] + Calcd for C 10 H 10 FN3Na214.0754,Found:214.0751.

[0148] Embodiment 15

[0149] 2-(1-Chloroethyl)-4-phenyl-2H-1,2,3-triazole 3o

[0150]

[0151] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2 mmol, 45 mg, 1.0 eq) and 2 mL of acetonitrile were added. Then bromochloroethane 2j (0.24 mmol, 34 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, the mixture was purified by column chromatography using petroleum ether / ethyl acetate (30:1) as eluent to obtain oily liquid 3o in 86% yield (36 mg). 1 H NMR (400MHz, Chloroform-d) δ7.88 (s, 1H), 7.79 (d, J = 7.4Hz, 2H), 7.44(t,J=7.3Hz,2H), 7.36(t,J=7.3Hz,1H), 4.77(t,J=6.4Hz,2H), 4.03(t,J=6.4Hz,2H). 13 C NMR(101MHz,Chloroform-d)δ148.3,131.4,130.1,128.9,128.6, 125.9,55.9,41.5.HRMS(ESI)m / z:[M+H] + Calcd for C 10 H 11 ClN3208.0622,Found: 208.0626.

[0152] Example 16

[0153] 2-(1-Chlorobutyl)-4-phenyl-2H-1,2,3-triazole 3p

[0154]

[0155] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2 mmol, 45 mg, 1.0 eq) and 2 mL of acetonitrile were added. Then bromochloroethane 2k (0.24 mmol, 41 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as the eluent, and the mixture was purified by column chromatography to obtain an oily liquid 3p in 85% yield (40 mg). 1 H NMR (400MHz, Chloroform-d) δ7.82 (s, 1H), 7.77 (d, J = 7.6Hz, 2H), 7.42(t,J=7.4Hz,2H),7.33(t,J=7.2Hz,1H),4.49(t,J=6.8Hz,2H),3.55(t,J=6.4Hz,2H),2.20–2.10(m,2H),1.86–1.74(m,2H). 13 C NMR(101MHz, Chloroform-d)δ147.7,130.8,130.4,128.9,128.4,125.8,54.1,44.1,29.4,27.1. HRMS(ESI)m / z:[M+H] + Calcdfor C 12 H 15 ClN3236.0940,Found:236.0949.

[0156] Embodiment 17

[0157] Ethyl 2,2-difluoro-2-(4-phenyl-2H-1,2,3-triazol-2-yl)acetate (3q)

[0158]

[0159] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole 1a (0.2 mmol, 45 mg, 1.0 eq) and 2 mL of acetonitrile were added. Then ethyl 2-bromo-2,2-difluoroacetate 2l (0.24 mmol, 48 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, the mixture was purified by column chromatography using petroleum ether / ethyl acetate (30:1) as eluent to obtain an oily liquid 3q in 85% yield (40 mg). 1 H NMR (400MHz, Chloroform-d) δ8.08 (s, 1H), 7.83 (d, J = 7.1 Hz, 2H), 7.53–7.42 (m, 3H), 4.53 (q, J = 7.0Hz, 2H), 1.43 (t, J = 7.1Hz, 4H). 19 F NMR(376MHz,Chloroform-d)δ-87.35. 13 C NMR(101MHz,Chloroform-d)δ 158.8,150.6,134.2,129.8,129.1,128.5,126.5,108.3(d,J=265.9Hz),64.6,13.8.HRMS(ESI)m / z:[M+H] + Calcd for C 12 H 12 F2N3O2 268.1943,Found:268.1949.

[0160] Embodiment 18

[0161] 2-Ethyl-4-(thiophen-3-yl)-2H-1,2,3-triazole (3r)

[0162]

[0163] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-(thiophene-3-yl)-1H-1,2,3-triazole 1g (0.2mmol, 46mg, 1.0eq) and 2mL of acetonitrile were added. Then bromoethane 2b (0.24mmol, 26mg, 1.2eq) and DBU (0.2mmol, 34mg, 2.0eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25°C) for 30 minutes. After the reaction was completed, the mixture was purified by column chromatography using petroleum ether / ethyl acetate (30:1) as eluent to obtain oily liquid 3r in 83% yield (30mg).1 H NMR (400MHz, Chloroform-d) δ7.71(s,1H),7.60(s,1H),7.44(d,J=4.8Hz,1H),7.40–7.36(m,1H),4.49(q,J=7.3Hz,2H),1.59(t,J=7.3Hz,3H). 13 C NMR(101MHz,Chloroform-d)δ143.7,131.8,130.8,126.4,125.9,121.3,50.1,14.9.HRMS(ESI)m / z:[M+H] + Calcd for C8H 10 N3S 180.1742,Found:180.1748.

[0164] Embodiment 19

[0165] 4-(Benzo[b]thiophen-3-yl)-2-ethyl-2H-1,2,3-triazole (3s)

[0166]

[0167] In a 4 mL sealed vial equipped with a stirring bar, 4-(Benzo[b]thiophen-3-yl)-1-(methylsulfonyl)-1H-1,2,3-triazole 1h (0.2 mmol, 56 mg, 1.0 eq) and 2 mL of acetonitrile were added. Ethyl bromide 2b (0.24 mmol, 26 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 °C) for 30 min. After the reaction was completed, the mixture was purified by column chromatography using petroleum ether / ethyl acetate (30:1) as the eluent to obtain 3s as an oily liquid in 80% yield (36 mg). 1 H NMR(400MHz,Chloroform-d)δ8.44(d,J=8.0Hz,1H), 7.91(d,J=6.3Hz,2H),7.71(s,1H),7.47(t,J=7.5Hz,1H),7.41(t,J=7.4Hz,1H),4.58(q,J=7.3Hz,2H),1.66(t,J=7.3Hz,3H). 13 C NMR(101MHz,Chloroform-d)δ143.2,140.4,136.9,131.8,126.6,124.7,124.7,124.2,123.8,122.7,50.1,14.9.HRMS(ESI)m / z:[M+H] +Calcd for C 12 H 12 N3S 230.0742; Found:230.0746.

[0168] Embodiment 20

[0169] 4-(Benzofuran-2-yl)-2-ethyl-2H-1,2,3-triazole (3t)

[0170]

[0171] In a 4 mL sealed vial equipped with a stirring bar, 4-(benzofuran-2-yl)-1-(methylsulfonyl)-1H-1,2,3-triazole 1i (0.2 mmol, 53 mg, 1.0 eq) and 2 mL of acetonitrile were added. Ethyl bromide 2b (0.24 mmol, 26 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, the mixture was purified by column chromatography using petroleum ether / ethyl acetate (30:1) as the eluent to obtain an oily liquid 3t in 85% yield (36 mg). 1 H NMR (400MHz, Chloroform-d) δ7.93 (s, 1H), 7.57 (dd, J=18.5, 7.8Hz, 2H), 7.38–7.17 (m, 2H), 4.54 (q, J=7.2Hz, 2H), 1.62 (t, J=7.3Hz, 3H). 13 C NMR (101MHz,Chloroform-d)δ154.7,147.8,139.7,131.6,128.5,124.7,123.2,121.1,111.4,103.2,50.3,14.8.HRMS(ESI)m / z:[M+H] + Calcd for C 12 H 12 N3O 214.0960; Found:214.0965.

[0172] Embodiment 21

[0173] 3-(2-Ethyl-2H-1,2,3-triazol-4-yl)quinoline (3u)

[0174]

[0175] In a 4 mL sealed vial equipped with a stirring bar, 3-(1-(methylsulfonyl)-1H-1,2,3-triazol-4-yl)quinoline 1j (0.2 mmol, 55 mg, 1.0 eq) and 2 mL of acetonitrile were added. Ethyl bromide 2b (0.24 mmol, 26 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were then added to the mixture, respectively. The vial was capped and stirred at room temperature (25 °C) for 30 minutes. After the reaction was completed, the mixture was purified by column chromatography using petroleum ether / ethyl acetate (30:1) as the eluent to obtain an oily liquid 3u in 85% yield (36 mg). 1 H NMR(400MHz,Chloroform-d)δ9.32(s,1H),8.47(s,1H),8.10(d,J= 8.5Hz,1H),7.97(s,1H),7.83(d,J=8.1Hz,1H),7.69(t,J=7.6Hz,1H),7.54(t,J=7.4Hz,1H),4.54(q,J=6.9Hz,2H),1.62(t,J=7.2Hz,3H). 13 C NMR(101MHz,Chloroform-d)δ148.4,147.8,144.7,131.9,131.1,129.6,129.3,127.9,127.8,127.1,123.7,50.3,14.8.HRMS(ESI)m / z:[M+H] + Calcd for C 13 H 13 N4 225.1140; Found: 225.1135.

[0176] Embodiment 22

[0177] 4-(2-(4-phenyl-2H-1,2,3-triazol-2-yl)ethyl)morpholine (3v)

[0178]

[0179] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole (0.2 mmol, 55 mg) 1a (0.2 mmol, 44 mg, 1.0 eq) and 2 mL of acetonitrile were added. Then 4-(2-bromoethyl)morpholine 2m (0.24 mmol, 46 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, the mixture was purified by column chromatography using petroleum ether / ethyl acetate (30:1) as eluent to obtain an oily liquid 3v in 81% yield (41 mg). 1 H NMR(400MHz,Chloroform-d)δ7.83(s,1H), 7.78(d,J=7.6Hz,2H),7.43(t,J=7.3Hz,2H),7.35(t,J=7.2Hz,1H),4.60(t,J=6.8Hz,2H),3.68(s,4H),3.00(t,J=6.8Hz,2H),2.53(s,4H). 13 C NMR(101MHz,Chloroform-d)δ147.7,130.9,130.4,128.8,128.4,125.8,66.9,57.5,53.4,52.3.HRMS(ESI)m / z:[M+H] + Calcd for C 14 H 19 N4O 259.1557; Found:259.1553.

[0180] Embodiment 23

[0181] 2-((4-phenyl-2H-1,2,3-triazol-2-yl)methyl)quinoline (3w)

[0182]

[0183] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole (0.2 mmol, 55 mg) 1a (0.2 mmol, 44 mg, 1.0 eq) and 2 mL of acetonitrile were added. Then 2-(bromomethyl)quinoline 2n (0.24 mmol, 53 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as the eluent and the mixture was purified by column chromatography to obtain 3w as a white solid in 81% yield (41 mg).1 H NMR (400MHz, Chloroform-d) δ8.10(t,J=8.8Hz,2H),7.95(s,1H),7.82(d,J=7.5Hz,2H),7.78(d,J=8.1Hz,1H),7.73(t ,J=7.6Hz,1H),7.53(t,J=7.4Hz,1H),7.43(t,J=7.3Hz,2H),7.35(t,J=7.3Hz,1H),7.14(d,J=8.5Hz,1H),5.99(s,2H). 13 C NMR(101MHz,Chloroform-d)δ155.5, 148.5,147.6,137.3,131.8,130.2,129.9,129.3,128.9,128.6,127.6,127.4,126.8,126.1,119.2,60.9.HRMS(ESI)m / z:[M+H] + Calcd for C 18 H 15 N4(M+H) + 287.1307; Found:287.1305.

[0184] Embodiment 24

[0185] 4-Phenyl-2-(thiophen-2-ylmethyl)-2H-1,2,3-triazole (3x)

[0186]

[0187] In a 4 mL sealed vial equipped with a stirring bar, 1-(methylsulfonyl)-4-phenyl-1H-1,2,3-triazole (0.2 mmol, 55 mg) 1a (0.2 mmol, 44 mg, 1.0 eq) and 2 mL of acetonitrile were added. Then 2-(bromomethyl)thiophene 2o (0.24 mmol, 42 mg, 1.2 eq) and DBU (0.2 mmol, 34 mg, 2.0 eq) were added to the mixture respectively. The vial was capped and stirred at room temperature (25 ° C) for 30 minutes. After the reaction was completed, petroleum ether / ethyl acetate (30:1) was used as the eluent and the mixture was purified by column chromatography to obtain a white solid 3x with an 83% yield (40 mg). 1H NMR(400MHz,Chloroform-d)δ7.87(s,1H),7.79 (d,J=7.6Hz,2H),7.43(t,J=7.5Hz,2H),7.35(t,J=7.3Hz,1H),7.29(d,J=5.1Hz,1H),7.16(d,J=2.6Hz,1H),6.99(t,J=4.2Hz,1H),5.79(s,2H). 13 C NMR (101MHz,Chloroform-d)δ148.2,136.8,131.6,130.2,128.8,128.5,127.6,127.1,126.6,126.1,53.2.HRMS(ESI)m / z:[M+H] + Calcd for C 13 H 12 N3S(M+H) + 242.1337; Found:242.1332.

[0188] Example 25 Anti-tumor cell activity test experiment:

[0189] 1. Inoculation of cells:

[0190] 1) A single cell suspension was prepared using DMEM culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 MG63 osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μL per well.

[0191] 2) A single cell suspension was prepared using RPMI1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 SJSA-1 osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μL per well.

[0192] 3) A single cell suspension was prepared using McCoy's 5A culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 HCT116 osteosarcoma cells were seeded into a 96-well cell culture plate in each well, with a volume of 100 μl per well.

[0193] 4) A single cell suspension was prepared using MEM culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 143B osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.

[0194] 2. Administration: The compound of formula (I) synthesized in the above examples of the present invention was prepared into a stock solution with a final concentration of 25 mM using DMSO, diluted to 1 μM using complete culture medium, and applied to cells in triplicate wells.

[0195] 3. Cultivation: Cultivate in an incubator with 5% CO2 and 37°C saturated humidity for 72 hours.

[0196] 4. Color development: After 72 hours of culture, aspirate the culture medium, add 100 μL complete culture medium and 10 μL CCK8 to each well, and incubate at 37°C for 4 hours.

[0197] 5. Colorimetry: Select 620nm and 450nm wavelengths, measure the optical density (OD) value of each well on the microplate reader, and record the results.

[0198] 6. For the same well, the absorbance value at 450 nm minus the absorbance value at 620 nm (background absorbance value) is used as the final absorbance and substituted into the following formula.

[0199] 7. Cell proliferation activity (%) = [A(drug added) - A(blank)] / [A(no drug added) - A(blank)] × 100%.

[0200] A (drug addition): absorbance of wells with osteosarcoma cells, CCK8 solution (Cell Counting Kit-8, a rapid and highly sensitive detection reagent for cell proliferation and cytotoxicity based on WST-8 (chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonylbenzene)-2H-tetrazolyl monosodium salt)) and drug solution (drug solution refers to DMSO solution of the compound sample to be tested)

[0201] A (blank): absorbance of wells with culture medium and CCK8 solution but no cells

[0202] A (no drug added): absorbance of the well with cells, CCK8 solution but no drug solution

[0203] 8. The experimental results show that: under the action of the compound of formula (I) of the present invention at a concentration of 100 μM, the survival rates of four different subtypes of osteosarcoma cells are shown in Table 1. This shows that compounds 3g and 3h show good inhibitory activity against osteosarcoma cells MG63; compounds 3h and 3b show relatively good inhibitory activity against osteosarcoma cells SJSA-1; compounds 3l and 3k show good inhibitory activity against osteosarcoma cells HCT116; and compounds 3h and 3i show relatively good inhibitory activity against osteosarcoma cells 143B.

[0204] Table 1

[0205]

[0206]

[0207] References:

[0208] 1.Gulevich,AV;Dudnik,AS;Chernyak,N.;Gevorgyan,V.Chem.Rev.,2013,113,3084.(d)Markos,A.;Janecky,L.; Chvojka,T.;Martinek,T.;Martinek-Seara,H.;Klepetarova,B.;Beiera,P.Adv.Synth.Catal.,2021,363,3258.

[0209] 2.Chen,YF;Liu,Y.-X.,Petersen,JL;Shi,XDChem.Commun.,2008,3254.

[0210] 3.Chen,YF;Liu,Y.-X.,Petersen,JL;Shi,XDChem.Commun.,2008,3254.

[0211] 4.Chen,YF;Liu,YX;Petersen,JL;Shi,XDChem.Comm.,2008.28.3254.

[0212] 5.Shi,JW;Zhu,LL;Wen,J.;Chen,Z.-L.Chin.J.Catal.,2016,37,1222。

Claims

1. A N 2 The use of an alkyl-substituted triazole derivative in the preparation of a drug having anti-tumor cell activity is characterized in that: The N 2 The structure of the alkyl-substituted triazole derivative is shown in formula (I), in, R 1 is C1-C12 alkyl, benzyl, quinolyl; R 2 is phenyl, halogen-substituted phenyl, C1-C10 alkyl-substituted phenyl, trifluoromethyl-substituted phenyl, or thienyl; The tumor cells are one or more of MG63 osteosarcoma cells, HCT116 colorectal cancer cells, SJSA-1 osteosarcoma cells, and 143B osteosarcoma cells.

2. A N 2 The use of an alkyl-substituted triazole derivative in the preparation of a drug having anti-tumor cell activity is characterized in that: The N 2 The structures of the alkyl-substituted triazole derivatives are as follows:

3. A N 2 A method for synthesizing an alkyl-substituted triazole derivative, characterized in that: The triazole compound shown in formula 1, the bromide or iodide shown in formula 2, and DBU base as an additive are reacted in an organic solvent to obtain N 2 Alkyl substituted triazole derivatives; the reaction process is shown in reaction formula (II): in, R 1 is C1-C12 alkyl, benzyl, quinolyl; R 2 It is phenyl, halogen-substituted phenyl, C1-C10 alkyl-substituted phenyl, trifluoromethyl-substituted phenyl, and thienyl.

4. The synthesis method according to claim 3, characterized in that The reaction temperature is room temperature; and / or the reaction time is 10-30 min.

5. The synthesis method according to claim 3, characterized in that The molar ratio of the triazole compound represented by Formula 1 to the bromide or iodide represented by Formula 2 is 1:1.2-1:1.5; and / or, the amount of the additive DBU is 100 mol%-200 mol% of the triazole compound based on the substituted triazole compound.

6. The synthesis method according to claim 3, characterized in that The organic solvent is selected from one or more of DCM, DCE, EA, toluene, and acetonitrile; and / or, the amount of the organic solvent is based on the triazole compound shown in substrate formula 1, so that the concentration of the triazole compound in the organic solvent ranges from 0.05M to 0.15M.

7. The synthesis method according to claim 3, characterized in that The method specifically comprises the following steps: First, the triazole compound represented by formula 1 is dissolved in the organic solvent, and then the brominated or iodinated compound represented by formula 2 is added at room temperature, and finally DBU is added as an additive to react to obtain the highly selective N 2 Alkyl substituted triazole derivatives.

8. The synthesis method according to claim 7, characterized in that Further, the N obtained by the reaction 2 The alkyl-substituted triazole derivatives are separated and purified; the separation and purification is performed by column chromatography using a solution with a volume ratio of ethyl acetate: petroleum ether of 1:30 to 1:20.

Citation Information

Patent Citations

  • Design of preparing novel organic OLED reagent from alcohol and application thereof

    CN105753794A

  • Method for constructing N-2-aryl-substituted-1,2,3-triazole

    CN107382886A

  • 1,2,3-Triazole derivatives as cannabinoid-receptor modulators

    EP1921072A1